➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
AstraZeneca
Moodys
Colorcon
Mallinckrodt

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Claims for Patent: 8,835,430


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,835,430
Title:2,4-pyrimidinediamine compounds and their uses
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Inventor(s): Singh; Rajinder (Belmont, CA), Argade; Ankush (Foster City, CA), Payan; Donald (Hillsborough, CA), Molineaux; Susan (San Francisco, CA), Holland; Sacha (San Francisco, CA), Clough; Jeffrey (Redwood City, CA), Keim; Holger (Irvine, CA), Bhamidipati; Somasekhar (Foster City, CA), Sylvain; Catherine (San Mateo, CA), Li; Hui (Santa Clara, CA), Rossi; Alexander (Reedsport, OR)
Assignee: Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:14/038,521
Patent Claims: 1. A compound according to the formula: ##STR00049## or a salt thereof, wherein: R.sup.2 is phenyl tri-substituted with the same or different R.sup.8 groups; R.sup.4 is phenyl substituted with one or more of the same or different R.sup.8 groups; R.sup.2 and R.sup.4 are different; R.sup.5 is halogen; R.sup.6 is hydrogen; R.sup.8 is selected from the group consisting of R.sup.a, R.sup.b, --O--(CH.sub.2).sub.m--R.sup.b, --S--(CH.sub.2).sub.m--R.sup.b, --O--CHR.sup.aR.sup.b, --O--CR.sup.a(R.sup.b).sub.2, --O--(CHR.sup.a).sub.m--R.sup.b, --C(O)NH--(CH.sub.2).sub.m--R.sup.b, --C(O)NH--(CHR.sup.a).sub.m--R.sup.b, --O--(CH.sub.2).sub.m--C(O)NH--(CH.sub.2).sub.m--R.sup.b, --S--(CH.sub.2).sub.m--C(O)NH--(CH.sub.2).sub.m--R.sup.b, --O--(CHR.sup.a).sub.m--C(O)NH--(CHR.sup.a).sub.m--R.sup.b, --NH--(CH.sub.2).sub.m--R.sup.b, --NH--(CHR.sup.a).sub.m--R.sup.b, --NH[(CH.sub.2).sub.mR.sup.b], --N[(CH.sub.2).sub.mR.sup.b].sub.2, --NH--C(O)--NH--(CH.sub.2).sub.m--R.sup.b, --NH--C(O)--(CH.sub.2).sub.m--CHR.sup.bR.sup.b and --NH--(CH.sub.2).sub.m--C(O)--NH--(CH.sub.2).sub.m--R.sup.b; each R.sup.a is independently selected from the group consisting of (C1-C6) alkyl, (C3-C8) cycloalkyl, cyclohexyl, (C4-C11) cycloalkylalkyl, (C5-C10) aryl, phenyl, (C6-C16) arylalkyl, benzyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl and 6-16 membered heteroarylalkyl; each R.sup.b is a suitable group independently selected from the group consisting of .dbd.O, --OR.sup.d, --OH, (C1-C3) haloalkyloxy, halogen, --CF.sub.3, --NO.sub.2, .dbd.N.sub.2, --N.sub.3, --S(O)R.sup.d, --S(O).sub.2R.sup.d, --S(O).sub.2OR.sup.d, --S(O)NR.sup.cR.sup.c, --S(O).sub.2NR.sup.cR.sup.c, --OS(O)R.sup.d, --OS(O).sub.2R.sup.d, --OS(O).sub.2OR.sup.d, --OS(O).sub.2NR.sup.cR.sup.c, --C(O)R.sup.d, --C(O)OR.sup.d, --C(O)NR.sup.cR.sup.c, OC(O)R.sup.d, --OC(O)OR.sup.d, --OC(O)NR.sup.cR.sup.c, --OC(NH)NR.sup.cR.sup.c, --OC(NR.sup.a)NR.sup.cR.sup.c, --[NHC(O)].sub.nR.sup.d, --[NR.sup.aC(O)].sub.nR.sup.d, --[NHC(O)].sub.nOR.sup.d, --[NR.sup.aC(O)].sub.nOR.sup.d, --[NHC(O)].sub.nNR.sup.cR.sup.c, --[NR.sup.aC(O)].sub.nNR.sup.cR.sup.c, --[NHC(NH)].sub.nNR.sup.cR.sup.c and --[NR.sup.aC(NR.sup.a)].sub.nNR.sup.cR.sup.c; each R.sup.c is independently hydrogen or R.sup.a, or, alternatively, each R.sup.c is taken together with the nitrogen atom to which it is bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different R.sup.a or suitable R.sup.b groups; each R.sup.d is independently hydrogen or R.sup.a; each m is independently an integer from 1 to 3; and each n is independently an integer from 0 to 3, with the provisos that the compound is not N2,N4-bis(3-methylphenyl)-5-fluoro-2,4-pyrimidinediamine; N2,N4-bis(3-chlorophenyl)-5-fluoro-2,4-pyrimidinediamine; N2,N4-bis(2,5-dimethylphenyl)-5-fluoro-2,4-pyrimidinediamine; N2,N4-bis(3,4-dimethylphenyl)-5-fluoro-2,4-pyrimidinediamine; N2,N4-bis(2,4-dimethylphenyl)-5-fluoro-2,4-pyrimidinediamine; N2,N4-bis(3-bromophenyl)-5-fluoro-2,4-pyrimidinediamine; N2,N4-bis[(3-chloro-4-methoxyphenyl)]-5-fluoro-2,4-pyrimidinediamine; N2,N4-Bis(3-chloro-4-methoxy)-5-fluoro-2,4-pyrimidinediamine; or a compound in which R.sup.2 is 3,4,5-trimethoxyphenyl.

2. The compound of claim 1, wherein R.sup.4 is mono-substituted with an R.sup.8 group.

3. The compound of claim 2, wherein R.sup.4 is ortho-substituted with the R.sup.8 group.

4. The compound of claim 2, wherein R.sup.4 is meta-substituted with the R.sup.8 group.

5. The compound of claim 2, wherein R.sup.4 is para-substituted with the R.sup.8 group.

6. The compound of claim 1, wherein R.sup.5 is fluoro.

7. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

8. The composition of claim 7, wherein the compound is in the form of a pharmaceutically acceptable salt.

9. The compound according to claim 1, provided R.sup.2 is not 3,4,5-tri(C.sub.1-C.sub.6)trialkoxyphenyl.

10. The compound of claim 9, wherein R.sup.4 is mono-substituted with an R.sup.8 group.

11. The compound of claim 10, wherein R.sup.4 is ortho-substituted with the R.sup.8 group.

12. The compound of claim 10, wherein R.sup.4 is meta-substituted with the R.sup.8 group.

13. The compound of claim 10, wherein R.sup.4 is para-substituted with the R.sup.8 group.

14. The compound of claim 9, wherein R.sup.5 is fluoro.

15. A pharmaceutical composition comprising a compound according to claim 9 and a pharmaceutically acceptable carrier, diluent or excipient.

16. The composition of claim 15, wherein the compound is in the form of a pharmaceutically acceptable salt.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Medtronic
Moodys
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.